Clonidine reduces elevated cerebrospinal fluid catecholamine levels in patients with essential hypertension.
Cerebrospinal fluid (CSF) catecholamines were measured in normotensive patients and in patients with mild to moderate essential hypertension. CSF-norepinephrine (NE) concentrations were 50% lower in the normotensive individuals (127 +/- 28 vs. 240 +/- 23 pg/ml) (P less than 0.01). In hypertensive patients, CSF-NE was inversely related to age (r = -0.68; P less than 0.01) and directly related to plasma NE (r = 0.61; P less than 0.05). Clonidine (450 mcg/day for 2 weeks) significantly reduced CSF-NE (-40%) in hypertensive patients. In addition, it decreased blood pressure, plasma and urinary NE. Urinary VMA was not affected by clonidine. No correlation was observed between clonidine effects on BP and on plasma or CSF catecholamines. This study indicates that patients with essential hypertension have elevated levels of CSF-NE which are reduced after treatment with clonidine. The elevation of CSF-NE suggests that central (spinal?) noradrenergic activity may be increased in patients with mild to moderate essential hypertension, and that can be reduced by treatment with clonidine.
D000328:Adult; D002395:Catecholamines / Q000097:blood / Q000134:cerebrospinal fluid* / Q000652:urine; D003000:Clonidine / Q000627:therapeutic use*; D004298:Dopamine / Q000134:cerebrospinal fluid; D004837:Epinephrine / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D006973:Hypertension / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000134:cerebrospinal fluid
D002395:Catecholamines; D003000:Clonidine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine